Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (13286)	1/13/1998 11:47:00 PM
From: Andrew H	Read Replies (3) \| Respond to of 32384

>> Targretin seems to be effective even against advanced patients who have failed prior therapies. I don't think that oncologists will be overly concerned about being sued for using Targretin. In fact they might be worried about the legal consequences of not trying the drug on termally ill patients.<< Any more info here? Still wondering about the breast cancer, since I have seen absolutely nothing about trials. We should hear soon about lung cancer. Did you hear Targretin was successful vs. prostate cancer as well? As far as LGND's low price, I have given up trying to figure it out but the large number of outstanding shares probably have something to do with it. However, it looks like profitability is coming a year sooner than expected and that no more dilution is necessary. Not many biotechs can say that. I guess we just have to wait for the market to catch up. Meanwhile far more powerful drugs than Targretin and Panretin are entering human trials. The future may be long but it should be good.